These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

633 related articles for article (PubMed ID: 29950526)

  • 1. The Role of Reed-Sternberg CD30 Receptor and Lymphocytes in Pathogenesis of Disease and Its Implication for Treatment.
    Rinaldi I
    Acta Med Indones; 2018 Apr; 50(2):93-95. PubMed ID: 29950526
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The European Medicines Agency Review of Brentuximab Vedotin (Adcetris) for the Treatment of Adult Patients With Relapsed or Refractory CD30+ Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use.
    Gravanis I; Tzogani K; van Hennik P; de Graeff P; Schmitt P; Mueller-Berghaus J; Salmonson T; Gisselbrecht C; Laane E; Bergmann L; Pignatti F
    Oncologist; 2016 Jan; 21(1):102-9. PubMed ID: 26621039
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD30 Downregulation, MMAE Resistance, and MDR1 Upregulation Are All Associated with Resistance to Brentuximab Vedotin.
    Chen R; Hou J; Newman E; Kim Y; Donohue C; Liu X; Thomas SH; Forman SJ; Kane SE
    Mol Cancer Ther; 2015 Jun; 14(6):1376-84. PubMed ID: 25840583
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD30+ Lymphoproliferative Disorders as Potential Candidates for CD30-Targeted Therapies.
    Schwarting R; Behling E; Allen A; Arguello-Guerra V; Budak-Alpdogan T
    Arch Pathol Lab Med; 2022 Apr; 146(4):415-432. PubMed ID: 35299246
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting CD30 Using Brentuximab Vedotin in the Treatment of Hodgkin Lymphoma.
    Alperovich A; Younes A
    Cancer J; 2016; 22(1):23-6. PubMed ID: 26841013
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Polyvalent Role of CD30 for Cancer Diagnosis and Treatment.
    Dumitru AV; Țăpoi DA; Halcu G; Munteanu O; Dumitrascu DI; Ceaușu MC; Gheorghișan-Gălățeanu AA
    Cells; 2023 Jul; 12(13):. PubMed ID: 37443818
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of CD30 targeting in malignant lymphoma.
    Kumar A; Younes A
    Curr Treat Options Oncol; 2014 Jun; 15(2):210-25. PubMed ID: 24570331
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD30: an important new target in hematologic malignancies.
    Deutsch YE; Tadmor T; Podack ER; Rosenblatt JD
    Leuk Lymphoma; 2011 Sep; 52(9):1641-54. PubMed ID: 21619423
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Brentuximab vedotin: new treatment for CD30+ lymphomas].
    Terriou L; Bonnet S; Debarri H; Demarquette H; Morschhauser F
    Bull Cancer; 2013; 100(7-8):775-9. PubMed ID: 23831822
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Hodgkin lymphoma].
    Nishikori M
    Rinsho Ketsueki; 2019; 60(5):447-452. PubMed ID: 31168012
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The epidemiology and targeted therapies for relapsed and refractory CD30+ lymphomas.
    Macalalad AR; McAuliffe M; Yang H; Kageleiry A; Zhong Y; Wu EQ; Shonukan O; Bonthapally V
    Curr Med Res Opin; 2015 Mar; 31(3):537-45. PubMed ID: 25598441
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD30 and CD30-Targeted Therapies in Hodgkin Lymphoma and Other B cell Lymphomas.
    Bhatt G; Maddocks K; Christian B
    Curr Hematol Malig Rep; 2016 Dec; 11(6):480-491. PubMed ID: 27613003
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Brentuximab vedotin in anaplastic large cell lymphoma.
    Skarbnik AP; Smith MR
    Expert Opin Biol Ther; 2012 May; 12(5):633-9. PubMed ID: 22449148
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Autocrine growth regulation of CD30 ligand in CD30-expressing Reed-Sternberg cells: distinction between Hodgkin's disease and anaplastic large cell lymphoma.
    Hsu PL; Hsu SM
    Lab Invest; 2000 Jul; 80(7):1111-9. PubMed ID: 10908157
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Brentuximab vedotin and crizotinib in anaplastic large-cell lymphoma.
    Foyil KV; Bartlett NL
    Cancer J; 2012; 18(5):450-6. PubMed ID: 23006951
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted therapy in relapsed classical hodgkin lymphoma.
    Dinner S; Advani R
    J Natl Compr Canc Netw; 2013 Aug; 11(8):968-76. PubMed ID: 23946175
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD30 ligand, a member of the TNF ligand superfamily, with growth and activation control CD30+ lymphoid and lymphoma cells.
    Gruss H-J ; Herrmann F
    Leuk Lymphoma; 1996 Feb; 20(5-6):397-409. PubMed ID: 8833395
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brentuximab vedotin: its role in the treatment of anaplastic large cell and Hodgkin's lymphoma.
    Haddley K
    Drugs Today (Barc); 2012 Apr; 48(4):259-70. PubMed ID: 22536568
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Brentuximab Vedotin (SGN-35), an antibody-drug conjugate for the treatment of CD30-positive malignancies.
    Gualberto A
    Expert Opin Investig Drugs; 2012 Feb; 21(2):205-16. PubMed ID: 22127011
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies.
    Bartlett NL; Chen R; Fanale MA; Brice P; Gopal A; Smith SE; Advani R; Matous JV; Ramchandren R; Rosenblatt JD; Huebner D; Levine P; Grove L; Forero-Torres A
    J Hematol Oncol; 2014 Mar; 7():24. PubMed ID: 24642247
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.